In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells

In vitro effectiveness of CB469, a MET tyrosine kinase inhibitor in MET-activated cancer cells

Abstract Gene alterations in receptor tyrosine kinases can result in oncogenic driver mutation in non-small cell lung cancer (NSCLC) including in genes like EGFR, ALK and MET. MET amplifications and MET exon14 skipping are the primary genetic changes in MET-altered cancers. Acquired MET mutations me...

Full description

Bibliographic Details
Main Authors: Ji Yeon Song, Hyunsook An, Soojeong Kim
Format: Article
Language:English
Published: SpringerOpen 2024-11-01
Series:Applied Biological Chemistry
Subjects:
Drug Resistance
capmatinib
Type I MET TKI
MET secondary mutation
Lung cancer
Online Access:https://doi.org/10.1186/s13765-024-00952-0

Internet

https://doi.org/10.1186/s13765-024-00952-0

Similar Items